SCHEMBL30125641

SCHEMBL30125641

COC(=O)CCNC(=O)c1nc(NC(=O)c2nc(NC(=O)CCNC(=O)c3nc(NC(=O)c4nccn4C)cn3C)cn2C)cn1C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
NAMPT P43490 1/20 0.38
KMT2A Q03164 1/20 0.37
ERBB2 P04626 1/20 0.35
RAB9A P51151 1/20 0.34
KDM5B Q9UGL1 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
VDR P11473 1/20 0.33
LDHA P00338 1/20 0.33
LDHB P07195 1/20 0.33
PKM P14618 1/20 0.33
GRM4 Q14833 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31180736 1.00 HDAC1 (0.42) HDAC1HDAC2HDAC8NAMPTKMT2A
SCHEMBL30125658 0.96 NAMPT (0.40) HDAC1HDAC2HDAC8NAMPTERBB2
SCHEMBL23728594 0.91 HDAC1 (0.55) HDAC1HDAC2HDAC8NAMPTERBB2
SCHEMBL23728639 0.90 HDAC1 (0.55) HDAC1HDAC2HDAC8NAMPTERBB2
SCHEMBL31180749 0.90 HDAC1 (0.43) HDAC1HDAC2HDAC8NAMPTKMT2A
SCHEMBL30125577 0.90 HDAC1 (0.43) HDAC1HDAC2HDAC8NAMPTKMT2A
SCHEMBL25809274 0.89 HDAC1 (0.57) HDAC1HDAC2HDAC8ERBB2KDM4E
SCHEMBL30125651 0.88 HDAC1 (0.59) HDAC1HDAC2HDAC8ERBB2
SCHEMBL31180737 0.87 HDAC1 (0.42) HDAC1HDAC2HDAC8NAMPTKMT2A
SCHEMBL30125670 0.87 HDAC1 (0.60) HDAC1HDAC2HDAC8ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360105-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. 2024-10-31 US disclosed
EP-4384506-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. (US) 2024-06-19 EP disclosed
WO-2023014793-A1 PROCESS FOR POLYAMIDE SYNTHESIS Design Therapeutics, Inc. (US) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360105-A1 PROCESS FOR POLYAMIDE SYNTHESIS POLI, POLR2A, POLR2B HDAC1 489/4885HDAC2 551/4885HDAC8 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.